Assembly Biosciences, INC Form 4 insider transactions

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, exercised stock options and sold shares to cover tax obligations, as reported in a recent SEC filing.

Anuj Gaggar, Chief Medical Officer of Assembly Biosciences, was granted stock options on March 29, 2025, according to a Form 4 filing.

Director Michael Houghton of Assembly Biosciences acquired 3,202 shares of common stock through an IRA at a weighted average price of $15.6145 per share.

Gilead Sciences, Inc. has acquired 940,499 shares of Assembly Biosciences, Inc. at a price of $21.37 per share, increasing its total holdings to 2,209,471 shares.

Director Alexander Schornstein of Assembly Biosciences, Inc. has increased his holdings through open market purchases of common stock.

Assembly Biosciences' Chief Manufacturing Officer, Nicole S. White, sold 40 shares of common stock at $16.29 per share to cover tax obligations related to vesting restricted stock units.

Director Alexander Schornstein purchased 10,000 shares of Assembly Biosciences (ASMB) at an average price of $14.58 on October 8, 2024.

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 157 shares of common stock on October 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Assembly Biosciences CEO Jason A. Okazaki sold 197 shares of common stock on October 3, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 785 shares of common stock on August 2, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

CEO of Assembly Biosciences, Jason A. Okazaki, sold 981 shares of common stock to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Alexander Schornstein, a director at Assembly Biosciences, recently purchased additional shares of the company's common stock in open market transactions.

Gilead Sciences purchased 179,500 shares of Assembly Biosciences common stock and warrants in a private placement, increasing its direct ownership.

Director Lisa Johnson-Pratt acquired 2,750 stock options in Assembly Biosciences, Inc. on May 29, 2024.

Director John G. McHutchison of Assembly Biosciences, Inc. was granted stock options to purchase 2,750 shares of common stock on May 29, 2024.

Susan Mahony, a director at Assembly Biosciences, was granted stock options to purchase 2,750 shares of common stock.

Director Michael Houghton of Assembly Biosciences, Inc. was granted stock options to purchase 2,750 shares of common stock on May 29, 2024.

Director Gina Consylman was granted stock options for 2,750 shares of Assembly Biosciences, Inc. (ASMB) on May 29, 2024.

Director Anthony E. Altig acquired 2,750 stock options in Assembly Biosciences, Inc. on May 29, 2024.

Director William Ringo acquired 2,750 stock options in Assembly Biosciences, Inc. on May 29, 2024.

Jeanette M. Bjorkquist, Principal Accounting Officer of Assembly Biosciences, sold shares to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

John G. McHutchison, a director at Assembly Biosciences, sold 2,117 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 172 shares of common stock to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Assembly Biosciences CEO Jason A. Okazaki sold 549 shares of common stock on May 23, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 1,255 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

CEO Jason Okazaki of Assembly Biosciences reports acquisition and disposition of company stock related to vesting of restricted stock units and covering tax obligations.

William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, acquired 3,333 shares of common stock on April 29, 2024, following the achievement of a performance-based vesting condition.

Director John G. McHutchison sold 1,206 shares of Assembly Biosciences (ASMB) on April 1, 2024, to cover tax withholding obligations related to vested restricted stock units.

Jeanette M. Bjorkquist, Principal Accounting Officer of Assembly Biosciences, reports acquisition and disposal of company stock and stock options related to vesting and tax obligations.

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 197 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.